Eculizumab is an anti-C5 antibody, but C5a receptor antagonists target C5a alone and do not inhibit MAC, so those antagonists may lessen risk of an infection with a pathogen such as Neisseria meningitidis seen with eculizumab. Here, C5 is linked to infection.